Skip to content
2000
Volume 22, Issue 5
  • ISSN: 1570-1794
  • E-ISSN: 1875-6271

Abstract

Introduction

The origin, synthesis, characterization and docking studies of ()-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((,1E,4E)-3-hydroxy-5-phenylpenta-1,4-dien-1-yl)cyclopentyl)-N-ethylhept-5-enamide, an impurity generated in the preparation of an anti-glaucoma agent-Bimatoprost has been described.

Methods

This impurity was controlled by employing 30% Pd/C, and the impurity level was brought to the permissible level, ., 0.03% (ICH guidelines) in the final drug preparation of Bimatoprost.

Results

Finally, induced-fit docking calculations were performed to theoretically evaluate the binding efficiencies of these inhibitors in the crystal structure of Prostaglandin F synthase (PGFS).

Conclusion

There are negligible differences in RMSD and docking scores between the two ligands, which amount to only 0.18 Å and 0.313 kcal/mol, respectively. These findings strongly indicate that both ligands are likely to exhibit similar biological functions and efficiencies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cos/10.2174/0115701794327619240924100026
2025-01-09
2025-07-19

  • From This Site

    /content/journals/cos/10.2174/0115701794327619240924100026
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LeeD. MantravadiA.V. MyersJ.S. Patient considerations in ocular hypertension: Role of bimatoprost ophthalmic solution.Clin. Ophthalmol.2017111273128010.2147/OPTH.S118689 28744094
     [Google Scholar]
  2. Guven YilmazS. DegirmenciC. KarakoyunY.E. YusifovE. AtesH. The efficacy and safety of bimatoprost/timolol maleate, latanoprost/timolol maleate, and travoprost/timolol maleate fixed combinations on 24-h IOP.Int. Ophthalmol.20183841425143110.1007/s10792‑017‑0601‑8 28616797
     [Google Scholar]
  3. BatraR. TailorR. MohamedS. Ocular surface disease exacerbated glaucoma: Optimizing the ocular surface improves intraocular pressure control.J. Glaucoma2014231566010.1097/IJG.0b013e318264cd68 22828007
     [Google Scholar]
  4. DigiuniM. FogagnoloP. RossettiL. A review of the use of latanoprost for glaucoma since its launch.Expert Opin. Pharmacother.201213572374510.1517/14656566.2012.662219 22348427
     [Google Scholar]
  5. MatsouA. AnastasopoulosE. Investigational drugs targeting prostaglandin receptors for the treatment of glaucoma.Expert Opin. Investig. Drugs2018271077778510.1080/13543784.2018.1526279 30227753
     [Google Scholar]
  6. HigginbothamE.J. SchumanJ.S. GoldbergI. GrossR.L. VanDenburghA.M. ChenK. WhitcupS.M. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension.Arch. Ophthalmol.2002120101286129310.1001/archopht.120.10.1286 12365906
     [Google Scholar]
  7. CantorL.B. HoopJ. MorganL. WuDunn, D.; Catoira, Y. Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension.Br. J. Ophthalmol.200690111370137310.1136/bjo.2006.094326 16825272
     [Google Scholar]
  8. HeijlA. LeskeM.C. BengtssonB. HymanL. BengtssonB. HusseinM. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial.Arch. Ophthalmol.2002120101268127910.1001/archopht.120.10.1268 12365904
     [Google Scholar]
  9. NoeckerR.S. DirksM.S. ChoplinN.T. BernsteinP. BatoosinghA.L. WhitcupS.M. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma.Am. J. Ophthalmol.20031351556310.1016/S0002‑9394(02)01827‑5 12504698
     [Google Scholar]
  10. GandolfiS. SimmonsS.T. SturmR. ChenK. VanDenburghA.M. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension.Adv. Ther.200118311012110.1007/BF02850299 11571823
     [Google Scholar]
  11. SimmonsS.T. DirksM.S. NoeckerR.J. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: Results from parallel-group comparison trials.Adv. Ther.200421424726210.1007/BF02850157 15605619
     [Google Scholar]
  12. AptelF. CucheratM. DenisP. Efficacy and tolerability of prostaglandin analogs: A meta-analysis of randomized controlled clinical trials.J. Glaucoma200817866767310.1097/IJG.0b013e3181666557 19092464
     [Google Scholar]
  13. ParrishR.K. PalmbergP. SheuW.P. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure.Am. J. Ophthalmol.2003135568870310.1016/S0002‑9394(03)00098‑9 12719078
     [Google Scholar]
  14. KymesS. BurkC. FeinmanT. WilliamsJ.M. HollanderD. Demonstration of an online tool to assist managed care formulary evidence-based decision making: Meta-analysis of topical prostaglandin analog efficacy.Ther. Clin. Risk Manag.2011728329010.2147/TCRM.S20495 21845051
     [Google Scholar]
  15. CravenE.R. LiuC.C. BatoosinghA. SchiffmanR.M. WhitcupS.M. A randomized, controlled comparison of macroscopic conjunctival hyperemia in patients treated with bimatoprost 0.01% or vehicle who were previously controlled on latanoprost.Clin. Ophthalmol.201041433144010.2147/OPTH.S14915 21188155
     [Google Scholar]
  16. RecchiaF.M. ScottI.U. BrownG.C. BrownM.M. HoA.C. IpM.S. Small-gauge pars plana vitrectomy: A report by the American Academy of Ophthalmology.Ophthalmology201011791851185710.1016/j.ophtha.2010.06.014 20816248
     [Google Scholar]
  17. KodaN. WatanabeK. TsutsuiY. NiwaH. ItoS. WoodwardD.F. Synthesis of prostaglandin f ethanolamide by PGF syn-thase and identification of bimatoprost as a potent PGFS inhibitor.Invest. Ophthalmol. Vis. Sci.20044533663
     [Google Scholar]
  18. KomotoJ. YamadaT. WatanabeK. WoodwardD.F. TakusagawaF. Prostaglandin F2α formation from prostaglandin H2 by prostaglandin F synthase (PGFS): Crystal structure of PGFS containing bimatoprost.Biochemistry20064571987199610.1021/bi051861t 16475787
     [Google Scholar]
  19. LuC. WuC. GhoreishiD. ChenW. WangL. DammW. RossG.A. DahlgrenM.K. RussellE. LuC. WuC. GhoreishiD. ChenW. WangL. DammW. RossG.A. DahlgrenM.K. RussellE. Von BargenC.D. AbelR. FriesnerR.A. HarderE.D. OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space.J. Chem. Theory Comput.20211774291430010.1021/acs.jctc.1c00302 34096718
     [Google Scholar]
  20. BanksJ.L. BeardH.S. CaoY. ChoA.E. DammW. FaridR. FeltsA.K. HalgrenT.A. MainzD.T. MapleJ.R. MurphyR. PhilippD.M. RepaskyM.P. ZhangL.Y. BerneB.J. FriesnerR.A. GallicchioE. BanksJ.L. BeardH.S. CaoY. ChoA.E. DammW. FaridR. FeltsA.K. HalgrenT.A. MainzD.T. MapleJ.R. MurphyR. PhilippD.M. RepaskyM.P. ZhangL.Y. BerneB.J. FriesnerR.A. GallicchioE. LevyR.M. Integrated Modeling Program, Applied Chemical Theory (IMPACT).J. Comput. Chem.200526161752178010.1002/jcc.20292 16211539
     [Google Scholar]
  21. HalgrenT.A. MurphyR.B. FriesnerR.A. BeardH.S. FryeL.L. PollardW.T. BanksJ.L. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening.J. Med. Chem.20044771750175910.1021/jm030644s 15027866
     [Google Scholar]
  22. OlssonM.H.M. SøndergaardC.R. RostkowskiM. JensenJ.H. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical p Ka Predictions.J. Chem. Theory Comput.20117252553710.1021/ct100578z 26596171
     [Google Scholar]
  23. Rama Mohana ReddyJ. Venkata NarayanaM. Venkata ReddyG. Krishna KanthiG. An efficient and laboratory friendly synthesis of anti-glaucoma agent of bimatoprost.Int. J. Pharma Sci.202112527162725
     [Google Scholar]
  24. HarikrishnaM. MohanH.R. DubeyP.K. ShankarM. SubbarajuG.V. Synthesis of(±)- Bimatoprost. Synth. Commun.20124291288130510.1080/00397911.2010.539754
     [Google Scholar]
  25. ReddyR.E. MaguireC.J. RelvasJ.D. AlleyS.R. O’DohertyM. DineenB.A. GradyH.L. RoartyT.J. Review of the Synthesis of Bimatoprost Drug Substance Used for the Treatment of Open-Angle Glaucoma.Org. Process Res. Dev.20232771220123410.1021/acs.oprd.3c00102
     [Google Scholar]
  26. WoodwardD.F. AndrewsS.W. BurkR.M. Non-acidic cyclopentane heptanoic, 2-cycloalkyl or ar-ylalkyl derivatives as therapeutic agents.US Patent 56888191997
  27. GarstM.E. OudenesJ. AntczakC.G. MortimerR.D. LuY.F. Preparation of prostamides.WO Patent 03074481A22003
  28. GutmanA. NisnevichG. A new process for the preparation of 1-phenyl-18,19,20-trinor-PGF2a and its derivatives.WO Patent 02096868A22002
  29. DeSouzaD. AlbertM. SturmH. Process for the production of bimatoprost.WO Patent 153206A22009
  30. ZanoniG. D’AlfonsoA. PortaA. FelicianiL. NolanS.P. VidariG. The Meyer–Schuster rearrangement: A new synthetic strategy leading to prostaglandins and their drug analogs.Bimatoprost and Latanoprost. Tetrahedron201066387472747810.1016/j.tet.2010.07.069
     [Google Scholar]
  31. DamsI. ChodyńskiM. KrupaM. PietraszekA. ZezulaM. CmochP. KosińskaM. KutnerA. A novel convergent synthesis of the antiglaucoma PGF2α analogue bimatoprost.Chirality201325317017910.1002/chir.22123 23381781
     [Google Scholar]
  32. AngeliA. SupuranC.T. Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018).Expert Opin. Ther. Pat.2019291079380310.1080/13543776.2019.1661992 31462124
     [Google Scholar]
  33. Rama Mohana ReddyJ. Venkata NarayanaM. Venkata ReddyG. Ravi KumarC. Isolation, Characterization, and Docking Studies of (Z)-Isopropyl 7-((1R, 2R, 3R, 5S)-2-((1E, 3Z)-3-Fluoro-4-Phenoxybuta-1, 3-Dienyl)-3,5-Dihydroxycyclopentyl) Hept-5-Enoate, an Impurity of Tafluprost.Curr. Org. Synth.20211816
     [Google Scholar]
  34. GordonM.O. KassM.A. The Ocular Hypertension Treatment Study: Design and baseline description of the participants.Arch. Ophthalmol.1999117557358310.1001/archopht.117.5.573 10326953
     [Google Scholar]
  35. BeanG.W. CamrasC.B. Commercially available prostaglandin analogs for the reduction of intraocular pressure: Similarities and differences.Surv. Ophthalmol.2008536Suppl. 1S69S8410.1016/j.survophthal.2008.08.012 19038626
     [Google Scholar]
  36. AlagözG. GürelK. BayerA. SerinD. ÇelebiS. KüknerŞ. A comparative study of bimatoprost and travoprost: Effect on intraocular pressure and ocular circulation in newly diagnosed glaucoma patients.Ophthalmologica20082222889510.1159/000112624 18303228
     [Google Scholar]
  37. CamrasC.B. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.Am. J. Ophthalmol.2002133573273310.1016/S0002‑9394(02)01396‑X 11992888
     [Google Scholar]
  38. CantorL.B. Bimatoprost: A member of a new class of agents, the prostamides, for glaucoma management.Expert Opin. Investig. Drugs200110472173110.1517/13543784.10.4.721 11281821
     [Google Scholar]
  39. FaridR. DayT. FriesnerR.A. PearlsteinR.A. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies.Bioorg. Med. Chem.20061493160317310.1016/j.bmc.2005.12.032 16413785
     [Google Scholar]
  40. ShermanW. BeardH.S. FaridR. Use of an induced fit receptor structure in virtual screening.Chem. Biol. Drug Des.2006671838410.1111/j.1747‑0285.2005.00327.x 16492153
     [Google Scholar]
  41. ShermanW. DayT. JacobsonM.P. FriesnerR.A. FaridR. Novel procedure for modeling ligand/receptor induced fit effects.J. Med. Chem.200649253455310.1021/jm050540c 16420040
     [Google Scholar]
  42. FriesnerR.A. MurphyR.B. RepaskyM.P. FryeL.L. GreenwoodJ.R. HalgrenT.A. SanschagrinP.C. MainzD.T. Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes.J. Med. Chem.200649216177619610.1021/jm051256o 17034125
     [Google Scholar]
  43. CoreyE.J. HelalC.J. Reduction of Carbonyl Compounds with Chiral Oxazaborolidine Catalysts: A New Paradigm for Enantioselective Catalysis and a Powerful New Synthetic Method.Angew. Chem. Int. Ed.199837151986201210.1002/(SICI)1521‑3773(19980817)37:15<1986:AID‑ANIE1986>3.0.CO;2‑Z 29711061
     [Google Scholar]
  44. VenkatanarayanaM. Ramamohana ReddyJ. Venkat ReddyG. Sharath BabuH. Identification and Efficient Synthetic Method for Preparation of Cyclopentane-1,3-diol Impurity in Tafluprost Drug.Asian J. Chem.202033121021410.14233/ajchem.2021.22934
     [Google Scholar]
  45. NakamuraC. KawasakiN. MiyatakaH. JayachandranE. KimI.H. KirkK.L. TaguchiT. TakeuchiY. HoriH. SatohT. Synthesis and biological activities of fluorinated chalcone derivatives.Bioorg. Med. Chem.200210369970610.1016/S0968‑0896(01)00319‑4 11814858
     [Google Scholar]
  46. LalG.S. LobachE. EvansA. Fluorination of thiocarbonyl compounds with Bis(2-methoxyethyl)aminosulfur trifluoride (Deoxo-fluor reagent): A facile synthesis of gem-difluorides.J. Org. Chem.200065164830483210.1021/jo000020j 10956459
     [Google Scholar]
  47. YangJ.M. ChenC.C. GEMDOCK: A generic evolutionary method for molecular docking.Proteins200455228830410.1002/prot.20035 15048822
     [Google Scholar]
/content/journals/cos/10.2174/0115701794327619240924100026
Loading
Synthesis, Characterization, and Docking Studies of 1,4-dien as a Potential Impurity in Bimatoprost Drug
Curr. Org. Synth. 22, 581 (2025); https://doi.org/10.2174/0115701794327619240924100026
/content/journals/cos/10.2174/0115701794327619240924100026
/content/journals/cos/10.2174/0115701794327619240924100026
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): Bimatoprost synthesis; docking studies; IFD calculations; novel diene impurity; Pd/C; prostaglandin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test